Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Response Dx GMBH

www.drugresponsedx.com

Latest From Fujifilm Holdings Corp.

2016 Review: Price Pressure Marks A Turbulent Year In Japan

If one theme dominated the Japanese pharma market in 2016 it was reimbursement pricing, with the regular price cuts in April being followed by political pressure over high-priced oncology drugs, and then major new reforms by the end of the year.

Japan Policy

From Solanezumab To Solithromycin: What To Watch For In Q4

Lilly’s solanezumab, Roche/Genentech’s Ocrevus and Cempra’s solithromycin are among the key therapies scheduled for major data read-outs or approval decisions in Q4 2016. With the help of Informa Pharma Intelligence’s Biomedtracker, Scrip takes a look at what to expect before we enter the new year.

Research & Development Policy & Regulation

Cynata Sets Stage For Global Fujifilm Cell Therapy Deal

Cynata has inched closer to a major global partnership after signing a term sheet with Fujifilm for cell therapy technologies that has been described by analysts as a potentially transformative deal.

Regenerative Medicine Deals

Nascent Deal Helps Hisun Advance Innovation Goals

Zhejiang Hisun Pharmaceuticals is continuing to enrich its pipeline through in-licensing deals, most recently with Nascent, while seeking out-licensing opportunities for its growing pipeline of clinical-stage biologics. The company is also looking to expand into other emerging markets through international partnerships, an executive says.

Commercial China
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Drug Response Dx GMBH
  • Senior Management
  • Zoltán Konthur, PhD, Managing Dir.
    Jörg-M. Hollidt, PhD, Managing Dir.
  • Contact Info
  • Drug Response Dx GMBH
    Phone: 3302 55199 85
    Neuendorfstr. 17
    Hennigsdorf, 16761
    Germany
Advertisement
Advertisement
UsernamePublicRestriction

Register